細胞バンク(東北大学・加藤研究室)


*担当者連絡先:東北大学大学院医学系研究科抗体創薬研究分野 加藤 幸成
    E-mail:yukinarikato(アットマーク)med.tohoku.ac.jp
*糖鎖遺伝子や糖タンパク質のKO細胞を順次登録していきます。
*アカデミアには、共同研究ベースで無償分譲します。(企業には有償。)
RIKENJCRBRIKEN東北大加齢研ATCC、企業(Thermo等)から親株を入手することが分譲の条件となります(各細胞のライセンスの問題があるため)。
*販売をご希望の企業からのご連絡をお待ちしております。
*どんな遺伝子のknockout細胞も、BINDSの支援で無償で作製しますので、ご相談ください。
 (共同研究ベースで、研究利用のみ。作製後は細胞バンクへ登録させて頂きます。)
抗体バンクもご覧下さい。
細胞名親株標的遺伝子ゲノム編集欠損販売
PDIS-1 HEK-293T hsMgat1/GnT-1 TALEN N-glycan -
PDIS-2 HEK-293T PDPN CRISPR/Cas9 PDPN ABM
PDIS-4 COS-7 PDPN CRISPR/Cas9 PDPN ABM
PDIS-5 CHO-S FUT8 CRISPR/Cas9 core-fucose -
PDIS-6 LN319 podoplanin/PDPN CRISPR/Cas9 podoplanin/PDPN -
細胞名親株標的遺伝子ゲノム編集欠損販売
PDIS-7 U87 MG podoplanin/PDPN CRISPR/Cas9 podoplanin/PDPN -
PDIS-9 CHO-S hsMgat1/GnT-1 TALEN N-glycan ABM
PDIS-12 HEK-293T hsMgat1/GnT-1 TALEN N-glycan ABM
PDIS-13 HEK-293T podocalyxin/PODXL CRISPR/Cas9 podocalyxin/PODXL -
PDIS-14 CHO-S SLC35A1 CRISPR/Cas9 sialic acid ABM
細胞名親株標的遺伝子ゲノム編集欠損販売
PDIS-18 HEK-293T SLC35A2 CRISPR/Cas9 galacose -
PDIS-20 HEK-293T GnT-1/SLC35A1/SLC35A2 TALEN and CRISPR/Cas9 N-glycan/sialic acid/galacose (triple-knockout) -
PDIS-22 HEK-293T SLC35A1 CRISPR/Cas9 sialic acid ABM
細胞名親株標的遺伝子ゲノム編集欠損販売
BINDS-01 SAS PODXL CRISPR/Cas9 PODXL
BINDS-02 HSC-2 PODXL CRISPR/Cas9 PODXL
BINDS-03 LN229 FUT8 CRISPR/Cas9 core-fucose
BINDS-04 LN229 hsMgat1/GnT-1 CRISPR/Cas9 N-glycan
BINDS-05 CHO-S GnT-1/SLC35A1 CRISPR/Cas9 N-glycan/sialic acid
細胞名親株標的遺伝子ゲノム編集作成中・予定販売
BINDS-06 HEK-293T GnT1/SLC35A1 CRISPR/Cas9 N-glycan/sialic acid
BINDS-07 CHO-S SLC35A2 CRISPR/Cas9 galacose
BINDS-08 HEK-293T GnT1 CRISPR/Cas9 N-glycan
BINDS-09 ExpiCHO-S FUT8 CRISPR/Cas9 core-fucose
BINDS-10 (平成30年度登録) *** CRISPR/Cas9 作成中:
DG44/ FUT8-KO
細胞名登録年度標的遺伝子ゲノム編集作成予定販売
BINDS-11 (平成31年度登録) *** CRISPR/Cas9 作成中:
DG44/N-glycan-KO
BINDS-12 (平成31年度登録) *** CRISPR/Cas9 作成中:
COS-7/GnT-1-KO
BINDS-13 (平成31年度登録) *** CRISPR/Cas9 作成中:
COS-7/FUT-8-KO
BINDS-** (平成31年度登録) *** CRISPR/Cas9 作成予定:
LN229/HER2-KO
BINDS-** (平成31年度登録) *** CRISPR/Cas9 作成予定:
LN229/EGFR-KO
細胞名登録年度標的遺伝子ゲノム編集作成予定販売
BINDS-** (平成32年度登録) *** CRISPR/Cas9 作成予定:
DG44/SLC35A1-KO
BINDS-** (平成32年度登録) *** CRISPR/Cas9 作成予定:
HSC-3/PD-L2-KO
BINDS-** (平成32年度登録) *** CRISPR/Cas9 作成予定:
LN229/CD44-KO
BINDS-** (平成32年度登録) *** CRISPR/Cas9 作成予定:
A431/EGFR-KO
BINDS-** (平成32年度登録) *** CRISPR/Cas9 作成予定:
A431/HER2-KO
細胞名登録年度標的遺伝子ゲノム編集作成予定販売
BINDS-** (平成33年度登録) *** CRISPR/Cas9 作成予定:
DG44/SLC35A2-KO
BINDS-** (平成33年度登録) *** CRISPR/Cas9 作成予定:
KMST-6/PD-L1-KO
BINDS-** (平成33年度登録) *** CRISPR/Cas9 作成予定:
KMST-6/PD-L2-KO
BINDS-** (平成33年度登録) *** CRISPR/Cas9 作成予定:
Caco-2/CD133-KO
BINDS-** (平成33年度登録) *** CRISPR/Cas9 作成予定:
HSC-3/PD-L1-KO
本セルバンクは、AMED創薬等支援技術基盤プラットフォーム(PDIS)およびAMED創薬ライフサイエンス研究支援基盤事業(BINDS)の成果です。上記の細胞は、共同研究ベースで供与可能です。

担当者連絡先:東北大学抗体創薬研究分野 加藤 幸成
E-mail:yukinarikato@gmail.com
抗体バンクもご覧下さい。

参考文献

  • PDIS-1
    1. Kaneko MK, Nakamura T, Honma R, Ogasawara S, Fujii Y, Abe S, Takagi M, Harada H, Suzuki H, Nishioka Y, Kato Y. Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN. Cancer Med., 6(2); 382-396, 2017
  • PDIS-2
    1. Kaneko MK, Nakamura T, Honma R, Ogasawara S, Fujii Y, Abe S, Takagi M, Harada H, Suzuki H, Nishioka Y, Kato Y. Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN. Cancer Med., 6(2); 382-396, 2017
    2. Fujii Y, Matsunaga Y, Arimori T, Kitago Y, Ogasawara S, Kaneko MK, Kato Y, Takagi J. Tailored placement of a turn-forming PA tag into the structured domain of a protein to probe its conformational state. J Cell Sci, 29, 1512-1522, 2016
    3. Ogasawara S, Kaneko MK, Kato Y. LpMab-19 Recognizes Sialylated O-glycan on Thr76 of Human Podoplanin. Monoclon. Antib. Immunodiagn. Immunother., DOI: 10.1089/ mab.2016.0031., 2016
    4. Ogasawara S, Kaneko MK, Honma R, Oki H, Fujii Y, Takagi M, Suzuki H, Kato Y.* Establishment of Mouse Monoclonal Antibody LpMab-13 against Human Podoplanin. Monoclon. Antib. Immunodiagn. Immunother., 35(3):155-162, 2016
    5. Kato Y*, Ogasawara Y, Oki H, Honma R, Takagi M, Fujii Y, Nakamura T, Saidoh N, Kanno H, Umetsu M, Kamata S, Kubo H, Yamada M, Sawa Y, Morita K, Harada H, Suzuki H, Kaneko MK. Novel Monoclonal Antibody LpMab-17 Developed by CasMab Technology Distinguishes Human Podoplanin from Monkey Podoplanin. Monoclon. Antib. Immunodiagn. Immunother., 35(2), 109-116, 2016
    6. Kato Y, Ogasawara S, Oki H, Goichberg P, Honma R, Fujii Y, Kaneko MK. LpMab-12 Established by CasMab Technology Specifically Detects Sialylated O-glycan on Thr52 of Platelet Aggregation-stimulating Domain of Human Podoplanin. PLoS One, 11(3), e0152912, 2016
  • PDIS-4
    1. Kato Y, Ogasawara S, Oki H, Goichberg P, Honma R, Fujii Y, Kaneko MK. LpMab-12 Established by CasMab Technology Specifically Detects Sialylated O-glycan on Thr52 of Platelet Aggregation-stimulating Domain of Human Podoplanin. PLoS One, 11(3), e0152912, 2016
  • PDIS-5
    1. Kaneko MK, Yamada S, Nakamura T, Abe S, Nishioka Y, Kunita A, Fukayama M, Fujii Y, Ogasawara S, Kato Y*. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity. Cancer Med.,,6(4): 768-777, 2017 (PDF)
  • PDIS-6
    1. Kaneko MK, Yamada S, Nakamura T, Abe S, Nishioka Y, Kunita A, Fukayama M, Fujii Y, Ogasawara S, Kato Y*. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity. Cancer Med., ,6(4): 768-777, 2017 (PDF)
    2. Kaneko MK, Nakamura T, Honma R, Ogasawara S, Fujii Y, Abe S, Takagi M, Harada H, Suzuki H, Nishioka Y, Kato Y. Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN. Cancer Med., 6(2); 382-396, 2017
    3. Shiina S, Ohno M, Ohka F, Kuramitsu S, Yamamichi A, Kato A, Motomura K, Tanahashi K, Yamamoto T, Watanabe R, Ito I, Senga T, Hamaguchi M, Wakabayashi T, Kaneko MK, Kato Y, Chandramohan V, Bigner DD, Natsume A.. CAR T cells targeting podoplanin reduce orthotopic glioblastomas in mouse brains. Cancer Immunol Res.;4(3):259-68.,2016 (PDF)
    4. Ogasawara S, Kaneko MK, Kato Y. LpMab-19 Recognizes Sialylated O-glycan on Thr76 of Human Podoplanin. Monoclon. Antib. Immunodiagn. Immunother., DOI: 10.1089/ mab.2016.0031., 2016
    5. Ogasawara S, Oki H, Kaneko MK, Hozumi Y, Liu X, Honma R, Fujii Y, Nakamura T, Goto K, Takagi M, Kato Y*. Development of a monoclonal antibody LpMab-10 recognizing non-glycosylated PLAG1/2 domain including Thr34 of human podoplanin. Monoclon. Antib. Immunodiagn. Immunother., 34(5), 318-326, 2015
    6. Kaneko MK, Oki H, Hozumi Y, Liu X, Ogasawara S, Takagi M, Goto K, Kato Y* A monoclonal antibody LpMab-9 recognizes O-glycosylated N-terminus of human podoplanin. Monoclon. Antib. Immunodiagn. Immunother., 34(5), 310-317, 2015
    7. Kato Y, Ogasawara S, Oki H, Goichberg P, Honma R, Fujii Y, Kaneko MK. LpMab-12 Established by CasMab Technology Specifically Detects Sialylated O-glycan on Thr52 of Platelet Aggregation-stimulating Domain of Human Podoplanin. PLoS One, 11(3), e0152912, 2016
  • PDIS-7
    1. Shiina S, Ohno M, Ohka F, Kuramitsu S, Yamamichi A, Kato A, Motomura K, Tanahashi K, Yamamoto T, Watanabe R, Ito I, Senga T, Hamaguchi M, Wakabayashi T, Kaneko MK, Kato Y, Chandramohan V, Bigner DD, Natsume A.. CAR T cells targeting podoplanin reduce orthotopic glioblastomas in mouse brains. Cancer Immunol Res.;4(3):259-68.,2016 (PDF)
  • PDIS-9
    1. Kaneko MK, Yamada S, Nakamura T, Abe S, Nishioka Y, Kunita A, Fukayama M, Fujii Y, Ogasawara S, Kato Y*. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity. Cancer Med., ,6(4): 768-777, 2017 (PDF)
    2. Kaneko MK, Nakamura T, Honma R, Ogasawara S, Fujii Y, Abe S, Takagi M, Harada H, Suzuki H, Nishioka Y, Kato Y. Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN. Cancer Med., 6(2); 382-396, 2017
  • PDIS-12
    1. Kaneko MK, Nakamura T, Honma R, Ogasawara S, Fujii Y, Abe S, Takagi M, Harada H, Suzuki H, Nishioka Y, Kato Y. Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN. Cancer Med., 6(2); 382-396, 2017
  • PDIS-13
    1. Ogasawara S, Kaneko MK, Yamada S, Honma R, Nakamura T, Saidoh N, Yanaka M, Yoshida K, Fujii Y, Kato Y.* PcMab-47: Novel Anti-human Podocalyxin Monoclonal Antibody for Immunohistochemistry. Monoclon. Antib. Immunodiagn. Immunother., DOI: 10.1089/mab.2017.0008, in press
  • PDIS-14
    1. Kaneko MK, Yamada S, Nakamura T, Abe S, Nishioka Y, Kunita A, Fukayama M, Fujii Y, Ogasawara S, Kato Y*. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity. Cancer Med., ,6(4): 768-777, 2017 (PDF)
    2. Kaneko MK, Nakamura T, Honma R, Ogasawara S, Fujii Y, Abe S, Takagi M, Harada H, Suzuki H, Nishioka Y, Kato Y. Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN. Cancer Med., 6(2); 382-396, 2017
  • PDIS-18
    1. Ogasawara S, Kaneko MK, Yamada S, Honma R, Nakamura T, Saidoh N, Yanaka M, Yoshida K, Fujii Y, Kato Y.* PcMab-47: Novel Anti-human Podocalyxin Monoclonal Antibody for Immunohistochemistry. Monoclon. Antib. Immunodiagn. Immunother., DOI: 10.1089/mab.2017.0008, in press
  • PDIS-20
    1. Ogasawara S, Kaneko MK, Yamada S, Honma R, Nakamura T, Saidoh N, Yanaka M, Yoshida K, Fujii Y, Kato Y.* PcMab-47: Novel Anti-human Podocalyxin Monoclonal Antibody for Immunohistochemistry. Monoclon. Antib. Immunodiagn. Immunother., DOI: 10.1089/mab.2017.0008, in press
  • PDIS-22
    1. Kaneko MK, Nakamura T, Honma R, Ogasawara S, Fujii Y, Abe S, Takagi M, Harada H, Suzuki H, Nishioka Y, Kato Y. Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN. Cancer Med., 6(2); 382-396, 2017
    2. Ogasawara S, Kaneko MK, Yamada S, Honma R, Nakamura T, Saidoh N, Yanaka M, Yoshida K, Fujii Y, Kato Y.* PcMab-47: Novel Anti-human Podocalyxin Monoclonal Antibody for Immunohistochemistry. Monoclon. Antib. Immunodiagn. Immunother., DOI: 10.1089/mab.2017.0008, in press